The WT1 gene is expressed in 73-100% of patients with acute myelogenous leukemia (AML) and is thought to play a role in maintaining the viability of leukemic cells. WT1 has been proposed as a marker for minimal residual disease in leukemia. We obtained serial blood or bone marrow samples from patients with de novo AML at diagnosis, during therapy, and up to 95 months after diagnosis and analyzed for WT1 gene expression by RT-PCR to determine whether gene expression was predictive of relapse. Forty-four patients had WT1-positive AML and achieved a complete remission (CR) following chemotherapy and 24 patients underwent unrelated donor (n = 4), sibling donor (n = 13) or autologous (n = 7) marrow transplantation. After achieving CR 62% of the patients became WT1-negative, while 38% remained WT1-positive. There was no difference in the disease-free survival (DFS) and survival from remission between WT1-positive and -negative patients (P Ͼ 0.1). Following BMT, 32% of the patients analyzed in CR within the first 100 days after transplantation were WT1 PCR positive. Detection of WT1 transcripts within 100 days following BMT did not affect DFS and overall survival (OS) after transplantation (P Ͼ 0.1). Ten of 11 patients who are in continuous CR following chemotherapy or BMT for more than 3 years were transiently WT1-positive during the observation period. Four of these patients displayed the WT1 transcript at the last examination. Thirteen of 39 patients were WT1 PCR negative within 4 months before clinical onset of relapse and eight patients were WT1 PCR negative at time of relapse. These data indicate that: (1) achievement of WT1 negativity is not associated with longer DFS, survival from remission, or OS after transplantation; (2) not all patients who relapse become WT1 positive again; (3) long-term remitters frequently display the WT1 transcript. Thus, we conclude that the monitoring of WT1 gene expression by qualitative RT-PCR during treatment and CR is of very limited value.
Introduction
The detection of residual leukemic blasts, once induction chemotherapy is complete, is important for both prognostic reasons and defining further treatment in patients with AML. The mainstays of detecting residual disease include karyotyping and immunophenotyping; however, sensitive polymerase chain reaction (PCR) may improve the ability to detect residual leukemic cells. Unfortunately, monitoring minimal residual disease (MRD) in AML is limited by the fact that specific target genes for PCR analysis are available in only a minority of patients. [1] [2] [3] [4] [5] [6] Furthermore, recent data indicate the frequent presence of karyotypic differences in AML blast cells at diagnosis and at relapse. 7 Several authors have found that the WT1 gene is frequently expressed in AML blast cells and have suggested that WT1 PCR analysis can be useful for monitoring MRD after conventional chemotherapy and bone marrow transplantation (BMT). [8] [9] [10] [11] [12] [13] [14] [15] [16] In addition, WT1 PCR analysis may also prove useful for the detection of residual blast cells in the bone marrow or in peripheral blood cells harvested for autologous BMT.
The WT1 gene is a provocative candidate for monitoring MRD. The gene, isolated by cytogenetic deletion analysis of patients with Wilms' tumor, is a candidate tumor suppressor gene located on chromosome 11p13. [17] [18] [19] WT1 is expressed during embryonic development in various tissues, as well as in some human malignancies. 20, 21 The gene consists of 10 exons, encoding a zinc finger transcription factor with four different alternatively spliced transcripts. The WT1 protein is involved in the regulation of growth and differentiation of cells and interacts with different target genes. 22 WT1 recognizes the early growth response (EGR)-1 DNA consensus sequence present in growth factor gene promoters such as the platelet derived growth factor A chain (PDGF-A) promoter and insulinlike growth factor II (IGF-II) promoter. [23] [24] [25] WT1 is thought to play a role in hematopoiesis and has been shown to repress the promoters of several genes expressed in hematopoietic cells (ie CSF-1, TGF-␤, RAR-␣, c-myc and bcl-2). Furthermore, recent data suggest that WT1 participates in leukemogenesis and that expression of a normal WT1 protein might maintain the viability of leukemia cells. [26] [27] [28] The aims of this study were: (1) to determine the prevalence of WT1 gene expression in AML patients, who achieved CR following conventional chemotherapy and in AML patients following BMT; (2) to investigate whether achievement of WT1 PCR negativity is associated with longer DFS, survival from remission, and OS after transplantation; (3) to determine the prevalence of WT1 PCR positivity at relapse, as well as in long-term remitters; and (4) to compare WT1 PCR results with bcr-abl (M0), PML/RAR␣ (M3), AML1/ETO (M2) and CBF␤/MYH11 (M1, M2, M4) PCR data.
Materials and methods

Patients
Adult patients with WT1 positive de novo AML diagnosed and treated at our institution between February 1988 and June 1995 were studied. Forty-four patients had achieved a CR following chemotherapy and 24 patients underwent BMT. Leukemia was classified according to the French-American-British Acute Leukemia Cooperative Group classification criteria (FAB) after examination of bone marrow (BM) aspirates stained by a modification of the Wright technique. In addition, immunophenotyping and karyotyping of BM were performed. Patients' characteristics are shown in 2 /day, days 1-5; n = 31); 14 of these patients took part in a randomized filgrastim trial. Eight patients with M3 received ATRA combined with or followed by chemotherapy. All patients received one to four consolidation courses including DA, DAV (at full or reduced doses) or high-dose Ara-C. Twentyfour patients underwent BMT from an HLA-identical unrelated (n = 4) or sibling (n = 13) donor or autologous BMT (n = 7) in first (n = 10) or second (n = 9) CR. Five patients were transplanted while not in CR ( Table 2 ). All patients who underwent BMT received one of the following conditioning regimens: cyclophosphamide (CY), fractionated total body irradiation (fTBI) or busulfan (BU), CY, fTBI. All patients received one or two doses of methotrexate (12 mg) intrathecally as part of the conditioning regimen. The clinical diagnosis of graft-versushost disease (GVHD) was confirmed by appropriate biopsies and clinically graded as 0-IV by the criteria reported for acute GVHD, 29 and as 'none', 'limited' or 'extensive' for chronic GVHD. 30 
Qualitative polymerase chain reaction (PCR)
Mononuclear cells from 375 peripheral blood (PB) or BM samples were isolated by density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway), immediately frozen and stored at −80°C until analyzed retrospectively by RT-PCR for the presence of WT1-specific mRNA. The mean observation time was 23 months (range 2 to 110 months). A median number of five samples was analyzed for each patient (range 2 to 17 samples per patient). All samples at diagnosis, at time of achievement of CR (mean time of 1 month after diagnosis, range 1 to 4 months), and the majority of samples at relapse (90%) were derived from BM. The majority of samples analyzed during CR following chemotherapy (78%) and BMT (76%) were PB specimens. WT1 PCR data were compared with PCR results for bcr-abl (M0), PML/RAR␣ (M3), AML1/ETO (M2) and CBF␤/MYH11 (M1, M2, M4) in the same patients.
Total RNA was extracted from 10 7 cells according to RNAzol B protocol (modified acid guanidinium thiocyanatephenol-chloroform method). 31 RNA pellets were resuspended in 25 l diethylpyrocarbonate-treated water and used directly for reverse transcription. 32 Amplification was performed in a Perkin Elmer thermocycler during one or when necessary, two subsequent rounds of PCR. AmpliTaq DNA Polymerase (Perkin Elmer Cetus, Norwalk, CT, USA), 2.5 mM MgCl 2 and 20 pmol of each primer in a total reaction volume of 50 l were used. Twenty microliter aliquots of the PCR products were electrophoresced on 1.5% agarose or 6% polyacrylamide (PML/RAR␣ PCR products) gels stained with ethidium bromide. The gels were photographed with Polaroid film (Polaroid 667; Polaroid, Hertfordshire, UK). Precautions against cross contamination were taken following the recommendations of Kwok and Higuchi. 33 Negative controls included the cDNA-and PCR-reagent mixes with water instead of cDNA in each experiment. To avoid false negatives, the presence of intact RNA and adequate cDNA generation was evaluated for each sample by a control PCR using ␤-actin or abl sequence-specific primers. Samples that did not amplify with these primers were excluded from analysis.
Oligonucleotides specific for abl exonII and bcr exon 2 (bcr-abl PCR), RAR␣ gene and PML gene exon III (PML/RAR␣ PCR), the AML1/ETO fusion transcript (AMLl/ETO PCR) and the CBF␤/MYH11 fusion transcript (CBF␤/MYH11 PCR) were synthesized according to published sequences and qualitative RT-PCR was performed as described previously. 2, 4, 6, 34 The level of sensitivity was 1:1000 after first step and 1:100 000 after second step PCR. 
WT1 PCR
Oligonucleotides specific for the WT1 gene were synthesized according to published sequences. 15, 35 Two subsequent rounds of PCR, for 35 cycles were performed under the following conditions: denaturation for 300 s at 94°C initially and 30 s in each subsequent cycle, annealing for 30 s at 64°C, and extension for 45 s at 72°C with a final extension step for an additional 7 min. The K562 cell line was used as a positive control. The PCR products have a size of 857 bp (first step) and 322 bp (second step), respectively. In order to ensure the specificity and sensitivity of our PCR procedure, hybridization was carried out using an oligonucleotide probe recognizing the WT1 sequence internal to the second step nested primers, which had been 5Ј end-labeled with digoxigenin (DIG Nucleic Acid Detection Kit; Boehringer Mannheim, Mannheim, Germany). The sequence of the oligonucleotide probe is 5Ј-CCA AAg gAg ACA TAC Agg TgT gAA ACC-3Ј. The level of sensitivity was 1:10 000 after the second step PCR.
Cytogenetics
Cytogenetic studies were carried out at the time of diagnosis in all patients. Unstimulated isolated BM cells were cultured for 24 to 48 h. Chromosomes were prepared and G-banding with trypsin was performed according to standard techniques as described. 36 When possible, 20 metaphases were analyzed and the results described according to the International System for Human Cytogenetic Nomenclature (ISCN).
Statistical analysis
We investigated the influence of WT1 gene expression on disease-free survival (DFS), survival from remission and survival after transplantation by plots of the product limit estimators 37 using BMDP1L (BMDP 1990 
Results
WT1 gene expression, following conventional chemotherapy, does not predict remission duration or relapse
Forty-four patients who had detectable WT1 mRNA at diagnosis and achieved CR were analyzed by PCR. After achieving CR 25 (62%) of the patients became WT1-negative, while 15 (38%) remained WT1-positive in the BM (Table 1) . Four patients were not evaluable for WT1 PCR analysis at the time of achieving CR. There was no correlation between WT1 PCR results at time of achieving CR when compared to age, sex, peripheral cell counts, FAB type, LDH and karyotype at diagnosis ( Table 1 ). The prevalence of WT1 positivity in the BM was similar in patients who did or did not receive filgrastim (data not shown). Furthermore, we could not observe any difference in DFS and survival from remission between WT1-positive and -negative patients (P Ͼ 0.1) (Figure 1a and b) .
Sixteen of 25 WT1-negative patients relapsed and 11 of these became WT1-positive, while three (patients 8, 9 and 33) remained negative despite relapse (Figure 2 ). Patient 43 was WT1 PCR negative at the time of achieving CR, became WT1-positive at first relapse, but was WT1-negative at second Achievement of WT1 negativity in the BM following conventional chemotherapy is not associated with longer DFS and survival from remission in AML patients. Probability of DFS (a) and survival from remission (b) according to Kaplan-Meier calculation in relation to WT1 mRNA expression at time of achievement of CR (NS).
relapse. One patient was not evaluable at time of relapse. Eleven of 15 WT1-positive patients relapsed and nine of these were WT1-positive, while patient 10 was negative at first relapse and patient 29 was negative at third relapse. There was no difference in the second CR rate between WT1-positive and -negative patients at relapse (data not shown). All six patients who are in continuous complete remission (CCR) for more than 3 years were either once (patients 21 and 31) or repeatedly (patients 24, 30, 39 and 40) WT1-positive in the PB during the observation period. Three of these patients were positive at the last examination (Figure 3a and b) . 
WT1 gene expression, following BMT, does not predict remission duration or relapse
Twenty-four patients who had detectable WT1 mRNA at diagnosis were analyzed by PCR following BMT. Seven of 22 patients (32%) analyzed in CR within the first 100 days after transplantation were WT1 PCR positive. There was no correlation between WT1 status and FAB subtype, disease status at time of transplantation, or the development of GVHD ( Table  2 ). All patients following autologous BMT were WT1-negative in BM and PB within 100 days after transplantation, whereas 5/12 patients following allogeneic and 2/4 patients following URD BMT displayed the WT1 transcript in BM (n = 3) or PB (n = 5) (Figure 3c ). WT1 PCR positivity within 100 days after BMT did not affect DFS and OS after transplantation (P Ͼ 0.1) (Figure 4a and b) . In the majority of patients (14/19) analyzed more than 100 days after BMT, WT1-specific mRNA could be detected in the peripheral blood. Two patients (patients 45 and 47) remained WT1 PCR negative despite relapse. Four of five patients who are in CCR for more than 3 years were once (patient 49) or repeatedly (patients 50, 51 and 58) WT1 PCR positive in PB (Figure 3c ).
In the majority of samples analyzed WT1 PCR results correlate with other markers of MRD
In order to investigate the reliability of our assay, we compared WT1 PCR data with the results of PML/RAR␣ and bcrabl PCR analyses, known to be predictive for relapse in 87 paired PB and BM samples. In 62% (54/87) of the samples analyzed concordant results were obtained and are shown in Figure 3b and c. In five of 10 patients initially displaying PML/RAR␣ specific mRNA PCR analysis revealed the presence of WT1-specific mRNA in CCR following chemotherapy (patients 37, 39 and 40) and BMT (patients 50 and 64), whereas PML/RAR␣ PCR remained negative. In patient 36 discordant results were due to the fact that although the patient displayed the t(15;17) no PML/RAR␣ specific mRNA could be detected using our PCR assay. In patient 44 with Philadelphia chromosome positive AML FAB M0, bcr-abl PCR remained positive throughout the entire observation period, whereas WT1 PCR was negative 3 and 3.5 months after diagnosis. Interestingly, quantitative Southern blot analysis 34 showed 5% residual bcr-abl rearranged cells 3.5 months after diagnosis, indicating that in this patient WT1 PCR failed to detect residual disease.
Additionally, we compared WT1 PCR data with the results of AML1/ETO and CBF␤/MYH11 PCR analyses, with not yet accurately determined value of MRD detection in 44 paired PB and BM samples. In 66% (29/44) of the samples analyzed concordant results were obtained and are shown in Figure 3b and c. All eight patients displaying AML1/ETO specific mRNA remained PCR positive throughout the entire observation period, whereas WT1 PCR became negative in three patients who remained in CCR (patients 30, 31 and 51). CBF␤/MYH11 PCR showed more positive results in the BM in patients with inv16 reflecting the slow disappearance of CBF␤/MYH11 transcripts during the first 7-11 months of remission (Ref. 40 and K Lechner, unpublished observations). Moreover, the persistence of PCR positivity with CBF␤/MYH11 may be a better indicator of impending relapse as in patients 42 and 43.
Overall, 131 paired PB and BM samples were analyzed. In 63% (83/131) of the samples analyzed concordant results were obtained. No differences in the rate of concordance between PCR systems predictive of relapse and those of not yet determined value were demonstrable.
Discussion
Data presented here demonstrate that the WT1 transcript is frequently expressed in AML patients during CR following chemotherapy and after marrow transplantation. We found that 38% (15/40) of our patients remained WT1-positive in the BM after achieving CR. The prevalence of WT1 positivity in CR is comparable to that of published studies: 30%, 9 36% 42 and 46%. 11 Comparison of our data with AML patients analyzed by Inoue et al 11 following chemotherapy within the first 6 months after diagnosis, revealed only minor differences in the prevalence of WT1 positivity between patients who remained in CR ( Achievement of WT1 negativity, in AML patients following BMT, is not associated with longer DFS and OS after transplantation. Probability of DFS (a) and OS after transplantation (b) in AML patients following BMT according to Kaplan-Meier calculation in relation to WT1 mRNA expression within 100 days after BMT (NS).
Inoue et al; 50%, 4/8). These observations are in contrast to Bergmann et al, 16 demonstrating that all patients achieving CR following chemotherapy became WT1-negative, whereas persistence of WT1 indicated treatment failure. Interestingly, previous reports of the same authors demonstrated WT1 gene expression in BM at time of achievement of CR in 6/20 9 and 5/14 41 patients.
Recent studies [9] [10] [11] 16 show a correlation between WT1 gene expression during CR and minimal residual disease in AML patients following chemotherapy and BMT, indicating that patients displaying high WT1 expression levels have a shorter remission duration compared with WT1-negative patients or those displaying only low amounts of the WT1 transcript. 11 We observed no difference in DFS and survival from remission between WT1-positive and -negative patients in CR following chemotherapy (P Ͼ 0.1), indicating that achievement of WT1 negativity in the BM is not associated with longer remission duration and survival from remission. Thus, detection of the WT1 transcript in the BM of patients at time of achieving CR might not reflect residual leukemic cells but 'physiological' WT1 gene expression detectable in normal BM or CD34
+ progenitor cells. 10, 12, 26, 42 Menssen et al 14 described WT1 gene expression during physiological expansion of immature CD34
+ hematopoietic progenitor cells during early clonogenic growth.
14 Interestingly, in our group of patients, the prevalence of WT1 gene expression was not effected by filgrastim therapy.
We observed a heterogeneity of WT1 gene expression in the peripheral blood of patients who remain in continuous CR. Ten of 11 patients who are in CCR for more than 3 years following chemotherapy and BMT were once (n = 3) or repeatedly (n = 7) positive during the observation period. Four of these patients were WT1-positive at the last examination, indicating the presence of WT1 transcripts despite long-term remission.
Inoue et al 10, 11 reported that the significance of low level WT1 gene expression in the PB of patients in clinical remission is unknown and hypothesized that low level WT1 positivity does not always predict imminent clinical relapse. In fact, the author and most recently Bergmann et al 16 hypothesized that the low level persistent WT1 gene expression may induce an anti-tumor immune response inhibiting the expansion of leukemic cells. We observed a high prevalence of WT1 PCR positivity in patients following allogeneic (11/13) and URD (4/4) marrow transplantation. In contrast to data from CML patients following allogeneic BMT, which indicates a significant correlation between bcr-abl PCR negativity and the presence of GVHD, 43 our results in AML patients following allogeneic BMT show no correlation between WT1 gene expression and GVHD and a possible associated graft-versusleukemia effect.
Clinical relevance of MRD has been thoroughly studied in acute promyelocytic leukemia, AML M2, CML and most recently in AML M1, M2 and M4 patients using CBF␤/MYH11 PCR analysis. One of the aims of this study was to compare WT1 with these parameters. No differences in the rate of concordance between PCR systems predictive of relapse (62%, PML/RAR␣ and bcr-abl PCR) and those of not yet determined value (66%, AML1/ETO and CBF␤/MYH11 PCR) were demonstrable. We found an overall correlation of 63% (81/131) in the samples analyzed. Comparison of WT1 PCR results with PML/RAR␣ PCR data indicated that detection of the WT1 transcript in the PB does not reflect the presence of residual leukemic cells in some patients. The reason for WT1 PCR positivity in these patients remains unclear, as the presence of MRD can be excluded by the negative PML/RAR␣ PCR results, and the level of WT1 gene expression in normal PB as reported recently 10 is below the detection limit of our WT1 PCR assay. Thus, WT1 PCR positivity in long-term remitters might not reflect residual leukemia in all patients but 'illegitimate or ectopic transcripts', or may have a physiological significance. 13 16 showed that recurrence of WT1 mRNA expression predicted clinical relapse. In our study population, 30/44 patients following chemotherapy and 9/24 patients after BMT suffered clinical relapse. Thirteen (33%) of these 39 patients were WT1 PCR negative within 4 months before clinical onset of relapse. Thirty-one patients were evaluable for WT1 PCR analysis at time of relapse and eight (26%) of these patients were WT1-negative at relapse. No difference in the second CR rate between WT1-positive and -negative patients at relapse was demonstrable. Thus, our data do not support the hypotheses that loss of WT1 gene expression at relapse represents a less or more aggressive leukemic clone.
The differences noted in our study as compared to the data reported by Inoue et al cannot solely be explained by (1) the higher sensitivity of their PCR system; (2) the use of quantitative PCR; or (3) the heterogeneity of patients analyzed (AML, ALL and CML). The relatively high prevalence of WT1 PCR negativity, despite apparent clinical relapse, might be due to the presence of karyotypic differences in AML blast cells at diagnosis and at relapse as has been reported. 7 Menssen et al 13 demonstrated a heterogeneity in WT1 protein expression at diagnosis within the leukemic cell population of a patient. Most leukemic MNC preparations contain WT1-negative blasts along with blasts that disclose strong nuclear fluorescence. What remains to be determined is whether the heterogeneous WT1 protein expression observed in freshly isolated leukemia blasts reflects blasts at different stages of differentiation which would indicate a hierarchy in AML progenitor cells 13, 14, 44 and might thus be related to their proliferative potential, or whether it is due to the presence of different WT1-positive and -negative clones at diagnosis. Our data support the hypothesis of WT1-positive and -negative clones present at diagnosis in some AML patients.
It must be emphasized that this is not a prospective study, and the treatment was not completely uniform, however, our data do not indicate that a prospective trial will show any differences. We conclude that monitoring of MRD using qualitative WT1 PCR analysis is of very limited if any value for several reasons: (1) achievement of WT1 PCR negativity in the BM is not associated with longer DFS and survival from remission; (2) the clinical significance of WT1 gene expression in the peripheral blood of long-term remitters remains to be elucidated and might not reflect residual leukemia in all patients; and (3) 26% of patients analyzed were WT1 PCR negative at time of relapse reflecting a possible genetic heterogeneity of AML blasts at diagnosis and relapse.
